It is worth noting that in the ND NPM1-mutant AML setting, the combination of HMA/VEN achieves long-lasting remissions, as reported by a recent multicenter study involving 221 participants (treated with 147 ICT, 74 HMA/VEN) and comparing this combination to standard induction ICT [132]. The gene discussed is NPM1; the disease is acute myeloid leukemia.